World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases

DCN Dx Acquires Human Biospecimen Provider BioSouthTech to Broaden Access to Diverse Patient Populations

Cision PR Newswire by Cision PR Newswire
October 29, 2026
in Press Releases
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Latin American collection network and banked specimens support broader patient representation and earlier-stage cancer research

CARLSBAD, Calif., Oct. 29, 2026 /PRNewswire/ — DCN Dx today announced its acquisition of BioSouthTech, Inc., a human biospecimen provider headquartered in the Miami area, with a collection network across Latin America, including South America, and access to specimens from the Caribbean. The acquisition expands DCN Dx’s sample bank and patient access for drug and diagnostic research.

Access to a broader range of patient specimens helps diagnostic developers study how their tests perform across different populations. BioSouthTech expands that access through its banked specimens and Latin American collection network.

“We started our biospecimens business to give researchers better access to patients and support the collections their studies require,” said Charlie Mamrak, CEO of DCN Dx. “Patient diversity was central to that decision. BioSouthTech gives our customers more ways to reach populations that their existing specimen sources may not represent.”

For developers of liquid biopsy assays, including multi-cancer early detection (MCED) and measurable residual disease (MRD) tests, specimens must reflect the disease stages and patient populations under study. The acquisition broadens DCN Dx’s sourcing options for oncology, neurology, and autoimmune disease research.

“You can’t develop a test for everyone on data from a few,” said Jim Boushell, senior vice president of biospecimens at DCN Dx. “For two decades, I’ve watched technology evolve on data that doesn’t quite reflect the patients those tests are meant to serve. We pursued BioSouthTech to give developers access to more diverse patient populations, including treatment-naive patients. Patient diversity must be part of the evidence.”

Starting now, DCN Dx customers can request characterized tissue and matched sets off the shelf or stand-up prospective collections designed to their own protocol across oncology, neurology, and infectious disease. The network already reaches patients across a range of ancestries and regions, and new geographies and expanded cohorts are planned for early 2027.

For more information about DCN Dx’s biospecimen services, visit dcndx.com/services/biospecimen.

About DCN Dx

For more than 20 years, DCN Dx has helped companies bring diagnostic tests to commercial success. The company combines an immunoassay CDMO, an IVD-dedicated CRO, and a biospecimen business offering banked specimens and direct collections. Its biospecimen team connects developers with diverse patient populations and specimens aligned to their study protocols and intended use. Direct collections operate under IRB/IEC oversight, with standardized protocols, clinical and demographic data, and chain-of-custody documentation. DCN Dx is based in Carlsbad, California. Learn more at dcndx.com.

MEDIA CONTACT
Media Relations
647.335.4623
425944@email4pr.com
DCNDx.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dcn-dx-acquires-human-biospecimen-provider-biosouthtech-to-broaden-access-to-diverse-patient-populations-302923660.html

SOURCE DCN Dx

Cision PR Newswire

Cision PR Newswire

Related Posts

Education in Motion Opens Dulwich College Bangkok, Setting New Standards for Sustainable Education in Thailand

November 10, 2026

GTN appoints former Gemini and Kraken executive Mark Jennings as global head of digital assets

November 10, 2026

Findity and Suiteify partner to launch Suiteify Expense & Travel in Germany

November 10, 2026

Agilyx ASA Q3 update: GreenDot on track for EUR 19 million EBITDA in 2026; Group EBITDA positive year to date

November 10, 2026

“All Access with Andy Garcia” to Explore Financial Planning Through Life’s Transitions with Manifest

November 10, 2026

EOS Holding – Gen Z and millennials: tech-savvy, financially under pressure

November 10, 2026

Popular News

  • Education in Motion Opens Dulwich College Bangkok, Setting New Standards for Sustainable Education in Thailand

    0 shares
    Share 0 Tweet 0
  • GTN appoints former Gemini and Kraken executive Mark Jennings as global head of digital assets

    0 shares
    Share 0 Tweet 0
  • Agilyx ASA Q3 update: GreenDot on track for EUR 19 million EBITDA in 2026; Group EBITDA positive year to date

    0 shares
    Share 0 Tweet 0
  • Findity and Suiteify partner to launch Suiteify Expense & Travel in Germany

    0 shares
    Share 0 Tweet 0
  • “All Access with Andy Garcia” to Explore Financial Planning Through Life’s Transitions with Manifest

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler